Reaction

Intermenstrual Bleeding reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 5,085 reports · 40 co-occurring drugs

As of the last recalculation, Intermenstrual Bleeding appears in 5,085 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is COPPER (PRR 73.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Copper	671	73.3	74.4
Etonogestrel	219	19.6	19.7
Progesterone	73	13.2	13.3
Emicizumab	36	12.0	12.0
Levonorgestrel	399	8.7	8.7
Estradiol Gel 0.1%	91	8.4	8.4
Estradiol Transdermal	91	8.4	8.4
Estradiol	134	6.5	6.5
Eltrombopag Olamine	33	5.9	5.9
Etonogestrel And Ethinyl Estradiol	23	4.3	4.3
Drospirenone And Ethinyl Estradiol	45	4.2	4.2
Tranexamic Acid	9	4.1	4.2
Ketoprofen	13	4.1	4.1
Human Immunoglobulin G	20	4.0	4.0
Fremanezumab-Vfrm	11	3.9	3.9
Goserelin	12	3.7	3.7
Indomethacin	11	3.4	3.4
Misoprostol	8	3.4	3.4
Amitriptyline Hydrochloride	14	3.3	3.3
Medroxyprogesterone Acetate	38	3.1	3.1
Relugolix	17	3.0	3.0
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, And Amphetamine Sulfate	23	2.7	2.7
Cariprazine	6	2.6	2.6
Oseltamivir Phosphate	15	2.5	2.5
Dextroamphetamine Sulfate, Dextroamphetamine Saccharate, Amphetamine Sulfate And Amphetamine Aspartate	25	2.5	2.5
Trifluridine And Tipiracil	6	2.3	2.3
Romiplostim	8	2.2	2.2
Tirzepatide	84	2.1	2.1
Elexacaftor, Tezacaftor, And Ivacaftor	6	2.0	2.0
Galcanezumab-Gnlm	15	2.0	2.0
Naltrexone Hydrochloride And Bupropion Hydrochloride	4	1.9	1.9
Alpelisib	3	1.4	1.4
Conjugated Estrogens And Medroxyprogesterone Acetate	8	1.4	1.4
Ofatumumab	11	1.4	1.4
Eptinezumab-Jjmr	3	1.3	1.3
Bimekizumab	6	1.2	1.2
Leuprolide Acetate	20	1.1	1.1
Rimegepant Sulfate	3	1.0	1.0
Voxelotor	3	0.5	0.5
Nirmatrelvir And Ritonavir	7	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.